Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3937251 | 0.84 | CHRNB2 (0.38) | CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL737230 | 0.79 | — | — | |
| SCHEMBL2879383 | 0.76 | CHRNB2 (0.38) | CHRNB2CHRNA4SIGMAR1GAAMAPT | |
| SCHEMBL587237 | 0.69 | CHRNB2 (0.39) | CHRNB2CHRNA4SIGMAR1GAAMAPT | |
| SCHEMBL444016 | 0.68 | CHRNB2 (0.42) | CHRNB2CHRNA4SIGMAR1GAAMAPT | |
| SCHEMBL549069 | 0.64 | — | — | |
| SCHEMBL29844361 | 0.64 | — | — | |
| SCHEMBL28850751 | 0.63 | PDE3B (0.35) | CHRNB2CHRNA4SIGMAR1GAAMAPT | |
| SCHEMBL736650 | 0.63 | — | — | |
| SCHEMBL3154784 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557130-B2 | Bicyclic heteroaromatic alanines | UCB PHARMA, S.A. (BE) | 2009-07-07 | — | — | US | disclosed |
| US-20040209913-A1 | e.g., 3-[1-(3,5-Dichloroisonicotinoyl)-2,3-dihydro-1 H-indol-5-yl]-2-[(3-oxo-spiro[3.5]non-1-en-1-yl)amino]-propanoate; modulating cell adhesion for the prophylaxis or treatment of inflammatory diseases or disorders, such as rheumatoid arthritis, in which the extravasculation of leukocytes plays a role. | UCB PHARMA S.A. (BE) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209913-A1 | e.g., 3-[1-(3,5-Dichloroisonicotinoyl)-2,3-dihydro-1 H-indol-5-yl]-2-[(3-oxo-spiro[3.5]non-1-en-1-yl)amino]-propanoate; modulating cell adhesion for the prophylaxis or treatment of inflammatory diseases or disorders, such as rheumatoid arthritis, in which the extravasculation of leukocytes plays a role. | ICAM1, VCAM1, CCR1 | CHRNB2 432/4885CHRNA4 256/4885SIGMAR1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.